-

12:15:13 PM

TCON Stock News

TCON - TRACON Pharmaceuticals Inc

05/16/22 8:05 AM

Nasdaq : TCON

conferenceslow float

TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to

RHEA-AI

neutral

05/11/22 4:02 PM

Nasdaq : TCON

earningslow float

TRACON Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

TRACON Pharmaceuticals, Inc. (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to

RHEA-AI

neutral

05/04/22 8:05 AM

Nasdaq : TCON

conferencesearningslow float

TRACON to Report First Quarter 2022 Financial Results and Corporate Update on May 11, 2022

TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to

RHEA-AI

neutral

04/19/22 8:05 AM

Nasdaq : TCON

low float

TRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K.

TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused

RHEA-AI

very positive

03/23/22 8:05 AM

Nasdaq : TCON

conferenceslow float

TRACON Pharmaceuticals to Present at the Maxim Group 2022 Virtual Growth Conference

TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to

RHEA-AI

neutral

03/15/22 4:02 PM

Nasdaq : TCON

earningslow float

TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update

TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical

RHEA-AI

positive

03/11/22 8:05 AM

Nasdaq : TCON

conferenceslow float

TRACON Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference

TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to

RHEA-AI

neutral

03/10/22 8:05 AM

Nasdaq : TCON

fda approvallow float

TRACON Pharmaceuticals Announces FDA Approval of Amended ENVASARC Protocol

TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and

RHEA-AI

very positive

03/04/22 8:05 AM

Nasdaq : TCON

conferencesearningslow float

TRACON to Report Fourth Quarter and Full Year 2021 Financial Results and Corporate Update on March 15, 2022

TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to

RHEA-AI

neutral

02/02/22 8:05 AM

Nasdaq : TCON

clinical triallow float

TRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer Institute

TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics today announced that the National Cancer Institute (NCI) has initiated a randomized

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

TCON Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.traconpharma.com
Security nameTRACON Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2836
Employees18
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing

About TRACON Pharmaceuticals Inc

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company's clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC253, a Phase 3 ready small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S.